CDK2 phosphorylation of Smad2 disrupts TGF-β transcriptional regulation in resistant primary bone marrow myeloma cells

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 1810-1817

  Baughn, Linda B ^a   Di Liberto, Maurizio ^a   Niesvizky, Ruben ^a   Cho, Hearn J ^b   Jayabalan, David ^a   Lane, Joseph ^a   Liu, Fang ^c   Chen Kiang, Selina ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MYC PROTEIN; PROTEIN BCL 2; SMAD2 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR; CDK2 PROTEIN, HUMAN; SMAD2 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CELL CYCLE ARREST; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; BONE MARROW CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM; MULTIPLE MYELOMA; PHOSPHORYLATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

APOPTOSIS; BONE MARROW CELLS; CYCLIN-DEPENDENT KINASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MULTIPLE MYELOMA; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 61449197711     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0713726     Document Type: Article

References (52)

1. Feng, X. H., and R. Derynck. 2005. Specificity and versatility in TGF-βsignaling through Smads. Annu. Rev. Cell. Dev. Biol. 21: 659-693.
2. Staller, P., K. Peukert, A. Kiermaier, J. Seoane, J. Lukas, H. Karsunky, T. Moroy, J. Bartek, J. Massague, F. Hanel, and M. Eilers. 2001. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell Biol. 3: 392-399.
3. Ink4B transcription in response to TGF-β. EMBO J. 19: 5178-5193.
4. Seoane, J., C. Pouponnot, P. Staller, M. Schader, M. Eilers, and J. Massague. 2001. TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat. Cell Biol. 3: 400-408.
5. Moustakas, A., and D. Kardassis. 1998. Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc. Natl. Acad. Sci. USA 95: 6733-6738.
6. Waf1/Cip1 regulation by transforming growth factor-β. J. Biol. Chem. 275: 29244-29256.
7. Reynisdottir, I., K. Polyak, A. Iavarone, and J. Massague. 1995. Kip/Cip and Ink4 CDK inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9: 1831-1845.
8. Scandura, J. M., P. Boccuni, J. Massague, and S. D. Nimer. 2004. Transforming growth factor β-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc. Natl. Acad. Sci. USA 101: 15231-15236.
9. Frederick, J. P., N. T. Liberati, D. S. Waddell, Y. Shi, and X. F. Wang. 2004. Transforming growth factor β-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol. Cell. Biol. 24: 2546-2559.
10. Yagi, K., M. Furuhashi, H. Aoki, D. Goto, H. Kuwano, K. Sugamura, K. Miyazono, and M. Kato. 2002. c-myc is a downstream target of the Smad pathway. J. Biol. Chem. 277: 854-861.
11. Yang, Y. A., G. M. Zhang, L. Feigenbaum, and Y. E. Zhang. 2006. Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2. Cancer Cell 9: 445-457.
12. Siegel, P. M., and J. Massague. 2003. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 3: 807-821.
13. Carrasco, D. R., G. Tonon, Y. Huang, Y. Zhang, R. Sinha, B. Feng, J. P. Stewart, F. Zhan, D. Khatry, M. Protopopova, et al. 2006. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9: 313-325.
14. Dong, M., and G. C. Blobe. 2006. Role of transforming growth factor-β in hematologic malignancies. Blood 107: 4589-4596.
15. Matsuura, I., N. G. Denissova, G. Wang, D. He, J. Long, and F. Liu. 2004. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430: 226-231.
16. Chen-Kiang, S. 2003. Cell-cycle control of plasma cell differentiation and tumorigenesis. Immunol. Rev. 194: 39-47.
17. Hayashi, T., T. Hideshima, A. N. Nguyen, O. Munoz, K. Podar, M. Hamasaki, K. Ishitsuka, H. Yasui, P. Richardson, S. Chakravarty, et al. 2004. Transforming growth factor βreceptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 10: 7540-7546.
18. Wright, N., T. L. de Lera, C. Garcia-Moruja, R. Lillo, F. Garcia-Sanchez, A. Caruz, and J. Teixido. 2003. Transforming growth factor-β1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 102: 1978-1984.
19. Urashima, M., A. Ogata, D. Chauhan, M. Hatziyanni, M. B. Vidriales, D. A. Dedera, R. L. Schlossman, and K. C. Anderson. 1996. Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells. Blood 87: 1928-1938.
20. Fernandez, T., S. Amoroso, S. Sharpe, G. M. Jones, V. Bliskovski, A. Kovalchuk, L. M. Wakefield, S. J. Kim, M. Potter, and J. J. Letterio. 2002. Disruption of transforming growth factor β signaling by a novel ligand-dependent mechanism. J. Exp. Med. 195: 1247-1255.
21. Amoroso, S. R., N. Huang, A. B. Roberts, M. Potter, and J. J. Letterio. 1998. Consistent loss of functional transforming growth factor βreceptor expression in murine plasmacytomas. Proc. Natl. Acad. Sci. USA 95: 189-194.
22. Ely, S., M. Di Liberto, R. Niesvizky, L. B. Baughn, H. J. Cho, E. N. Hatada, D. M. Knowles, J. Lane, and S. Chen-Kiang. 2005. Mutually exclusive cyclindependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res. 65: 11345-11353.
23. Durie, B. G. 1986. Staging and kinetics of multiple myeloma. Semin. Oncol. 13: 300-309.
24. Klein, B., X. G. Zhang, M. Jourdan, J. Content, F. Houssiau, L. Aarden, M. Piechaczyk, and R. Bataille. 1989. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73: 517-526.
25. INK4c and IL-6. Immunity 6: 47-56.
26. Kip1. Proc. Natl. Acad. Sci. USA 101: 17789-17794.
27. Fry, D. W., P. J. Harvey, P. R. Keller, W. L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W. R. Leopold, N. K. Pryer, and P. L. Toogood. 2004. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3: 1427-1438.
28. Liu, F., C. Pouponnot, and J. Massague. 1997. Dual role of the Smad4/DPC4 tumor suppressor in TGFβ-inducible transcriptional complexes. Genes Dev. 11: 3157-3167.
29. Do, R. K., E. Hatada, H. Lee, M. R. Tourigny, D. Hilbert, and S. Chen-Kiang. 2000. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med. 192: 953-964.
30. Sui, G., C. Soohoo, B. Affar el, F. Gay, Y. Shi, W. C. Forrester, and Y. Shi. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99: 5515-5520.
31. Long, J., G. Wang, I. Matsuura, D. He, and F. Liu. 2004. Activation of Smad transcriptional activity by protein inhibitor of activated STAT3 (PIAS3). Proc. Natl. Acad. Sci. USA 101: 99-104.
32. Hilbert, D. M., T. S. Migone, M. Kopf, W. J. Leonard, and S. Rudikoff. 1996. Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway. Immunity 5: 81-89.
33. Baughn, L. B., M. Di Liberto, K. Wu, P. L. Toogood, T. Louie, R. Gottschalk, R. Niesvizky, H. Cho, S. Ely, M. A. Moore, and S. Chen-Kiang. 2006. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 66: 7661-7667.
34. Hannon, G. J., and D. Beach. 1994. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371: 257-261.
35. Koff, A., M. Ohtsuki, K. Polyak, J. M. Roberts, and J. Massague. 1993. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-β. Science 260: 536-539.
36. 467 is required for Smad2-Smad4 complex formation and signaling. J. Biol. Chem. 272: 27678-27685.
37. 467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-β signaling. J. Biol. Chem. 272: 28107-28115.
38. Laiho, M., J. A. DeCaprio, J. W. Ludlow, D. M. Livingston, and J. Massague. 1990. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62: 175-185.
39. Iavarone, A., and J. Massague. 1997. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature 387: 417-422.
40. Derynck, R., R. J. Akhurst, and A. Balmain. 2001. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 29: 117-129.
41. Brown, R., A. Murray, B. Pope, D. M. Sze, J. Gibson, P. J. Ho, D. Hart, and D. Joshua. 2004. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br. J. Haematol. 125: 743-748.
42. Campbell, J. D., G. Cook, S. E. Robertson, A. Fraser, K. S. Boyd, J. A. Gracie, and I. M. Franklin. 2001. Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGFβ is reversed by IL-15. J. Immunol. 167: 553-561.
43. Cook, G., J. D. Campbell, C. E. Carr, K. S. Boyd, and I. M. Franklin. 1999. Transforming growth factor βfrom multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J. Leukocyte Biol. 66: 981-988.
44. Seoane, J. 2006. Escaping from the TGFβ anti-proliferative control. Carcinogenesis 27: 2148-2156.
45. Matsuura, I., G. Wang, D. He, and F. Liu. 2005. Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry 44: 12546-12553.
46. Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, C. Sidman, G. Proetzel, D. Calvin, et al. 1992. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359: 693-699.
47. Letterio, J. J., and A. B. Roberts. 1998. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16: 137-161.
48. Ehrhardt, R. O., W. Strober, and G. R. Harriman. 1992. Effect of transforming growth factor (TGF)-beta 1 on IgA isotype expression: TGF-beta 1 induces a small increase in sIgA+ B cells regardless of the method of B cell activation. J. Immunol. 148: 3830-3836.
49. van Vlasselaer, P., J. Punnonen, and J. E. de Vries. 1992. Transforming growth factor-beta directs IgA switching in human B cells. J. Immunol. 148: 2062-2067.
50. Cazac, B. B., and J. Roes. 2000. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13: 443-451.
51. Klein, J., W. Ju, J. Heyer, B. Wittek, T. Haneke, P. Knaus, R. Kucherlapati, E. P. Bottinger, L. Nitschke, and B. Kneitz. 2006. B cell-specific deficiency for Smad2 in vivo leads to defects in TGF-β-directed IgA switching and changes in B cell fate. J. Immunol. 176: 2389-2396.
52. Yang, X., J. J. Letterio, R. J. Lechleider, L. Chen, R. Hayman, H. Gu, A. B. Roberts, and C. Deng. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J. 18: 1280-1291.